CA2263828A1 - Polyprolyl inhibitors of cyclophilin - Google Patents

Polyprolyl inhibitors of cyclophilin Download PDF

Info

Publication number
CA2263828A1
CA2263828A1 CA002263828A CA2263828A CA2263828A1 CA 2263828 A1 CA2263828 A1 CA 2263828A1 CA 002263828 A CA002263828 A CA 002263828A CA 2263828 A CA2263828 A CA 2263828A CA 2263828 A1 CA2263828 A1 CA 2263828A1
Authority
CA
Canada
Prior art keywords
pro
seq
amino acid
xaa
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002263828A
Other languages
English (en)
French (fr)
Inventor
Gregory S. Hamilton
Ling Wei
Joseph P. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2263828A1 publication Critical patent/CA2263828A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002263828A 1996-12-09 1997-12-08 Polyprolyl inhibitors of cyclophilin Abandoned CA2263828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76190296A 1996-12-09 1996-12-09
US08/761,902 1996-12-09
PCT/US1997/023102 WO1998025950A1 (en) 1996-12-09 1997-12-08 Polyprolyl inhibitors of cyclophilin

Publications (1)

Publication Number Publication Date
CA2263828A1 true CA2263828A1 (en) 1998-06-18

Family

ID=25063558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263828A Abandoned CA2263828A1 (en) 1996-12-09 1997-12-08 Polyprolyl inhibitors of cyclophilin

Country Status (8)

Country Link
EP (1) EP0966479A4 (es)
JP (1) JP2001505920A (es)
AR (1) AR010744A1 (es)
AU (1) AU5702698A (es)
CA (1) CA2263828A1 (es)
PA (1) PA8442401A1 (es)
WO (1) WO1998025950A1 (es)
ZA (1) ZA9710989B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098897B1 (en) 1998-07-17 2004-06-09 Agouron Pharmaceuticals, Inc. Compounds, compositions, and methods for stimulating neuronal growth and elongation
AU5606400A (en) 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
HUP0202249A3 (en) 1999-07-09 2003-01-28 Ortho Mcneil Pharm Inc Neurotrophic pyrrolidines and piperidines, compositions containing them and use of the compounds
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
SK11452002A3 (sk) * 2000-02-11 2003-03-04 Vertex Pharmaceuticals Incorporated Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
EP3164148A4 (en) 2014-06-25 2017-12-13 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
SG11202010016QA (en) 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
JP2782142B2 (ja) * 1992-07-23 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害剤及びその製造法
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤

Also Published As

Publication number Publication date
WO1998025950A1 (en) 1998-06-18
EP0966479A4 (en) 2004-12-08
AU5702698A (en) 1998-07-03
ZA9710989B (en) 1999-05-25
JP2001505920A (ja) 2001-05-08
EP0966479A1 (en) 1999-12-29
PA8442401A1 (es) 2000-05-24
AR010744A1 (es) 2000-07-12

Similar Documents

Publication Publication Date Title
JP3248584B2 (ja) フィブロネクチン接着抑制剤
Adang et al. Case histories of peptidomimetics: progression from peptides to drugs
TWI364291B (en) Peptidic vasopressin receptor agonists
JP4540606B2 (ja) βセクレターゼ阻害活性を有するペプチド誘導体
US6316405B1 (en) Cyclosporin a conjugates and uses therefor
TW408133B (en) Bradykinin antagonist peptides incorporating N-substituted glycines
EP1644023A2 (en) Melanocortin recptor 4(mc4) agonists and their uses
IE914156A1 (en) Hiv protease inhibitors
JPH07504155A (ja) ブラジキニンアンタゴニストペプチド
US5817756A (en) Pseudo- and non-peptide bradykinin receptor antagonists
CA2263828A1 (en) Polyprolyl inhibitors of cyclophilin
WO1992015321A1 (en) Endothelin antagonists
US20040204340A1 (en) Polyprolyl inhibitors of cyclophilin
JP3878983B2 (ja) トリ、テトラ、ペンタ、及びポリペプチド、及びその抗抑欝症剤としての治療用途
CN101379076A (zh) 新化合物
US6207639B1 (en) Compounds and methods for modulating neurite outgrowth
US6333307B1 (en) Compounds and method for modulating neurite outgrowth
US20230040236A1 (en) Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
US20220024978A1 (en) Peptides comprising opioid receptor agonist and nk1 receptor antagonist activities
AU2021217939A1 (en) Reverse amide-linked melanocortin receptor-specific cyclic peptides
Kumarasinghe et al. Modification of Peptides to Limit Metabolism
US20030068321A1 (en) Methods of effecting neuronal activity
EP3966223A1 (en) Peptidomimetic agents, synthesis and uses thereof
WO2014075137A1 (en) Peptides incorporating amino-substituted lactams for treatment of retinopathy
Bladon Analogue and conformational studies on peptide hormones and other biologically active peptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued